GlobeImmune Inc., a Louisville, Colorado-based company developing novel therapies for patients with cancer and infectious diseases, announced a Series E Preferred Stock financing of $17.5m.
The round was led by new investors Generali Financial Holding and BSI SA, with participation from existing investors.
As stated by Timothy C. Rodell, M.D., CEO of GlobeImmune, this financing will strengthen the company’s balance sheet as it continue to move its clinical programs forward.
FinSMEs
19/10/2010
